Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Unicycive Therapeutics, a clinical stage biotechnology company focused on therapies for kidney disease, announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Shalabh Gupta will provide a corporate overview via a virtual presentation available on demand starting at 7:00 am ET on September 12. The presentation will be accessible for 90 days on their website. Unicycive is developing innovative treatments for hyperphosphatemia and acute kidney injury.

Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction

LOS ALTOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Company management will participate at the upcoming H.C. Wainwright 24^th Annual Global Investment Conference taking place September 12-14, 2022 in New York City. Shalabh Gupta, M.D., Chairman and Chief Executive Officer of Unicycive, will virtually present a corporate overview, which will be available On-Demand beginning at 7:00 am ET on Monday, September 12, 2022 through the end of the conference.

A webcast of Dr. Gupta’s presentation will also be available on the Investors section of the Unicycive website at https://ir.unicycive.com/events-presentations/ir-calendar, where it will be available for approximately 90 days following the event.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.

Investor Contact:

ir@unicycive.com
(650) 900-5470

Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
212-362-1200

SOURCE: Unicycive Therapeutics, Inc.

FAQ

What is the focus of Unicycive Therapeutics?

Unicycive Therapeutics specializes in developing therapies for kidney diseases.

When will Unicycive present at the H.C. Wainwright Conference?

Unicycive will present on September 12, 2022, during the H.C. Wainwright 24th Annual Global Investment Conference.

Who will be presenting for Unicycive at the conference?

CEO Shalabh Gupta will be presenting a corporate overview for Unicycive.

How can I access Unicycive's presentation?

The presentation will be available on demand starting September 12 on Unicycive's website.

What is Renazorb?

Renazorb is Unicycive's lead drug, designed as a phosphate binding agent for treating hyperphosphatemia.

What is UNI-494?

UNI-494 is a new chemical entity in late preclinical development aimed at treating acute kidney injury.